What is Bayside Laboratories?
Established in 1968, Bayside Laboratories operates as a full-service, CLIA-certified diagnostic facility. The company provides a comprehensive suite of clinical testing services, including bacteriology, immunology, and toxicology, serving a diverse clientele that spans healthcare providers, pharmaceutical firms, and emerging MedTech enterprises. Known for its commitment to rapid, next-day results, the laboratory integrates state-of-the-art diagnostic technology with a team of highly decorated industry professionals. This combination of legacy expertise and modern analytical precision allows Bayside to maintain a competitive edge in the high-stakes diagnostic market, prioritizing patient outcomes through rigorous quality control and world-class customer support.
How much funding has Bayside Laboratories raised?
Bayside Laboratories has raised a total of $335K across 2 funding rounds:
Debt
$150K
Debt
$185K
Debt (2020): $150K with participation from PPP
Debt (2021): $185K led by PPP
Key Investors in Bayside Laboratories
PPP
Public-Private Partnership
What's next for Bayside Laboratories?
With this late-stage capital, Bayside Laboratories is positioned to scale its diagnostic throughput and potentially expand its service footprint beyond the New York Metro Area. The strategic focus will likely center on upgrading laboratory automation to further reduce turnaround times and enhancing its digital integration with healthcare provider networks. As the diagnostic industry shifts toward more personalized medicine and complex molecular testing, Bayside's ability to deploy this financing effectively will be critical in maintaining its market share against national competitors. The firm is expected to prioritize investments in advanced instrumentation and talent acquisition to sustain its long-term growth trajectory and operational excellence.
See full Bayside Laboratories company page
